Annexin Pharmaceuticals in collaboration for COVID-19 study
Physicians in the Netherlands plan to start a COVID-19 study with Annexin Pharmaceuticals drug candidate ANXV and have to this end submitted an application to the local authority. Annexin Pharmaceuticals will provide ANXV and has secured funding to take part in the study.A medical research team at the Maastricht University Hospital, The Netherlands has proposed an investigator initiated clinical trial to evaluate the safety and potential effects of ANXV treatment in patients with moderate to severe COVID-19. Previously published findings in COVID-19 patients show that ANXV could dampen